Marker Therapeutics (MRKR) Current Assets (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Current Assets of $17.4 million for Q1 2026, up 2.59% year-over-year from $17.0 million in Q1 2025, and down 8.58% quarter-over-quarter from $19.1 million in Q4 2025.
Marker Therapeutics (MRKR) Current Assets (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Current Assets for 17 consecutive years, with $17.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 2.59% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $17.4 million (up 2.59% YoY), while the FY2025 annual figure was $19.1 million, down 13.4% from the prior year.
- Current Assets fell to $17.4 million in Q1 2026 per MRKR's latest filing, from $19.1 million in the prior quarter.
- Across five years, Current Assets topped out at $31.0 million in Q1 2022 and bottomed at $10.9 million in Q3 2024.
- Historically, Current Assets has averaged $18.7 million across 5 years, with a median of $17.4 million in 2026.
- Annual changes were most pronounced in 2023 — Current Assets slumped 64.82% — and 2025, when it soared 99.21%.
- Marker Therapeutics' Current Assets stood at $16.6 million in 2022, then advanced by 3.06% to $17.1 million in 2023, then increased by 28.58% to $22.0 million in 2024, then declined by 13.4% to $19.1 million in 2025, then decreased by 8.58% to $17.4 million in 2026.
- Business Quant data shows MRKR's Current Assets at $17.4 million in Q1 2026, $19.1 million in Q4 2025, and $21.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 14.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.43 Mn |
| Dec 31, 2025 | 19.07 Mn |
| Sep 30, 2025 | 21.73 Mn |
| Jun 30, 2025 | 14.77 Mn |
| Mar 31, 2025 | 16.99 Mn |
| Dec 31, 2024 | 22.02 Mn |
| Sep 30, 2024 | 10.91 Mn |
| Jun 30, 2024 | 11.68 Mn |
| Mar 31, 2024 | 14.09 Mn |
| Dec 31, 2023 | 17.13 Mn |
| Sep 30, 2023 | 19.49 Mn |
| Jun 30, 2023 | 21.96 Mn |
| Mar 31, 2023 | 10.91 Mn |
| Dec 31, 2022 | 16.62 Mn |
| Sep 30, 2022 | 22.42 Mn |
| Jun 30, 2022 | 29.28 Mn |
| Mar 31, 2022 | 31.02 Mn |
| Dec 31, 2021 | 45.98 Mn |
| Sep 30, 2021 | 51.41 Mn |
| Jun 30, 2021 | 60.02 Mn |